CA2546763A1 - Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants - Google Patents
Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants Download PDFInfo
- Publication number
- CA2546763A1 CA2546763A1 CA002546763A CA2546763A CA2546763A1 CA 2546763 A1 CA2546763 A1 CA 2546763A1 CA 002546763 A CA002546763 A CA 002546763A CA 2546763 A CA2546763 A CA 2546763A CA 2546763 A1 CA2546763 A1 CA 2546763A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- epha2
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des procédés et des compositions conçus pour le traitement, la maîtrise, ou la prévention du cancer, notamment le cancer métastatique. Les procédés consistent à administrer une quantité efficace d'un ou plusieurs anticorps qui se lient à l'activité d'EphA2 et qui la renforcent, augmentant ainsi la phosphorylation de l'EphA2 et de faire baisser les niveaux d'EphA2 dans les cellules dans lesquelles l'activité d'EphA2 a été renforcée. L'invention concerne aussi des anticorps qui se lient de préférence à un épitope d'EphA2 exposé sur des cellules cancéreuses et non sur des cellules non cancéreuses, et des compositions pharmaceutiques contenant une ou plusieurs anticorps d'EphA2 de l'invention soit seuls, soit en combinaison avec un ou plusieurs autres agents utiles dans le traitement du cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52417703P | 2003-11-20 | 2003-11-20 | |
US60/524,177 | 2003-11-20 | ||
PCT/US2004/039112 WO2005051307A2 (fr) | 2003-11-20 | 2004-11-19 | Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2546763A1 true CA2546763A1 (fr) | 2005-06-09 |
Family
ID=34632874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002546763A Abandoned CA2546763A1 (fr) | 2003-11-20 | 2004-11-19 | Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1689346A4 (fr) |
JP (1) | JP4860477B2 (fr) |
KR (1) | KR20060135671A (fr) |
CN (1) | CN1905899B (fr) |
AU (1) | AU2004293034B2 (fr) |
CA (1) | CA2546763A1 (fr) |
WO (1) | WO2005051307A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
WO2004014292A2 (fr) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci |
US7662770B2 (en) | 2002-05-23 | 2010-02-16 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
CA2518912A1 (fr) | 2003-03-12 | 2004-09-23 | Vasgene Therapeutics, Inc. | Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale |
US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
DK1730196T3 (da) | 2004-03-12 | 2011-03-28 | Vasgene Therapeutics Inc | EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst |
AU2005224081B2 (en) | 2004-03-12 | 2011-06-30 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
EP1778726A4 (fr) | 2004-08-16 | 2009-03-18 | Medimmune Inc | Antagonistes de l'intégrine possédant une action cytotoxique à médiation cellulaire dépendante de l'anticorps améliorée |
WO2006034455A2 (fr) | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
EP1968998A4 (fr) * | 2005-12-21 | 2010-01-27 | Medimmune Llc | Anticorps agonistes d'epha2 à affinités optimisées et méthodes d'utilisation de ces anticorps |
CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
WO2009023185A1 (fr) | 2007-08-13 | 2009-02-19 | Vasgene Therapeutics, Inc. | Traitement contre le cancer utilisant des anticorps humanisés qui se lient à ephb4 |
PT2199390T (pt) * | 2007-08-30 | 2017-03-15 | Daiichi Sankyo Co Ltd | Anticorpo anti-epha2 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
RU2598711C2 (ru) * | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
WO2016171242A1 (fr) * | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Détection d'epha2 |
CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1242060E (pt) * | 1999-08-17 | 2006-08-31 | Glaxo Group Ltd | Tratamento da doenca metastatica |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
WO2003094859A2 (fr) * | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation |
WO2004014292A2 (fr) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci |
WO2005056766A2 (fr) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 |
-
2004
- 2004-11-19 JP JP2006541599A patent/JP4860477B2/ja not_active Expired - Fee Related
- 2004-11-19 AU AU2004293034A patent/AU2004293034B2/en not_active Expired - Fee Related
- 2004-11-19 KR KR1020067012152A patent/KR20060135671A/ko not_active Application Discontinuation
- 2004-11-19 CN CN2004800407205A patent/CN1905899B/zh not_active Expired - Fee Related
- 2004-11-19 CA CA002546763A patent/CA2546763A1/fr not_active Abandoned
- 2004-11-19 WO PCT/US2004/039112 patent/WO2005051307A2/fr active Application Filing
- 2004-11-19 EP EP04811773A patent/EP1689346A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20060135671A (ko) | 2006-12-29 |
CN1905899B (zh) | 2011-09-28 |
WO2005051307A3 (fr) | 2006-09-08 |
JP2008500021A (ja) | 2008-01-10 |
JP4860477B2 (ja) | 2012-01-25 |
CN1905899A (zh) | 2007-01-31 |
AU2004293034B2 (en) | 2012-02-02 |
WO2005051307A2 (fr) | 2005-06-09 |
EP1689346A4 (fr) | 2007-11-21 |
AU2004293034A1 (en) | 2005-06-09 |
EP1689346A2 (fr) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009239780B2 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
EP1519956B1 (fr) | Anticorps monoclonaux contre epha2 et leurs methodes d'utilisation | |
US20100143345A1 (en) | Epha2 agonistic monoclonal antibodies and methods of use thereof | |
AU2004293034B2 (en) | EphA2 agonistic monoclonal antibodies and methods of use thereof | |
US7604799B2 (en) | EphA4 Antibodies | |
US20050153923A1 (en) | Targeted drug delivery using EphA2 or EphA4 binding moieties | |
US20090220527A1 (en) | Affinity optimized epha2 agonistic antibodies and methods of use thereof | |
AU2012202569A1 (en) | EPHA2 agonistic monoclonal antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20130528 |
|
FZDE | Discontinued |
Effective date: 20130528 |